AntimicrobialIn Clinical Trials

Omiganan

Topical

Overview

Omiganan is a synthetic 12-amino acid cationic antimicrobial peptide derived from indolicidin, a naturally occurring peptide from bovine neutrophils. It acts by disrupting microbial membranes and demonstrates activity against bacteria, fungi, and some viruses.

Mechanism of Action

Omiganan was developed as a topical agent to prevent catheter-related bloodstream infections through its broad-spectrum antimicrobial properties. Its small size and potent activity made it a candidate for preventing biofilm formation on medical devices..

Research Summary & Key Findings

Phase III trials evaluated omiganan as a catheter site antiseptic gel but did not demonstrate statistically significant reduction in catheter-related bloodstream infections compared to standard care. The FDA issued a Complete Response Letter in 2007 citing insufficient efficacy data. Subsequent development has focused on rosacea and other dermatologic indications, with Phase II trials conducted in acne vulgaris.

Clinical Status

In Clinical Trials

Omiganan is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

Topical

Related Peptides in Antimicrobial

Find a Provider

Find a verified provider who offers Omiganan therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Omiganan.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.